Clearside Biomedical, Inc.
CLSD
$3.70
-$0.39-9.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.17% | 11.89% | -5.75% | 14.57% | 6.75% |
| Total Depreciation and Amortization | 199.07% | 253.75% | 237.31% | 142.03% | 17.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.11% | -39.11% | -18.12% | -4.81% | 10.69% |
| Change in Net Operating Assets | -572.26% | -284.73% | -332.92% | 95.22% | 225.94% |
| Cash from Operations | -13.68% | -20.82% | -36.19% | 21.82% | 21.51% |
| Capital Expenditure | 51.58% | 45.96% | 45.02% | 62.64% | 28.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 203.08% | -- | -- | -- | -- |
| Cash from Investing | 189.95% | 65.68% | 64.10% | -475.80% | -727.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -77.17% | -83.90% | 831.75% | 846.12% | 1,058.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00% | 25.93% | -- | -185.71% | -103.30% |
| Cash from Financing | -86.00% | -89.32% | 3,870.05% | 1,031.62% | -54.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.15% | -258.29% | 54.35% | 39.71% | -388.49% |